Real-world direct healthcare costs of treating recurrent high-grade serous ovarian cancer with cytotoxic chemotherapy

Lucy Gilbert; Agnihotram V Ramanakumar; Maria Carolina Festa; Kris Jardon; Xing Zeng; Claudia Martins; Layla Shbat; Marwa Abo Alsoud; Manuel Borod; Michael Wolfson; Ioanna Papaioannou; Olga Basso; John Sampalis

doi:10.2217/cer-2020-0032

Real-world direct healthcare costs of treating recurrent high-grade serous ovarian cancer with cytotoxic chemotherapy

J Comp Eff Res. 2020 Jun;9(8):537-551. doi: 10.2217/cer-2020-0032. Epub 2020 Mar 30.

Authors

Lucy Gilbert^{1

2

3}, Agnihotram V Ramanakumar⁴, Maria Carolina Festa^{1

2}, Kris Jardon^{1

2

3}, Xing Zeng^{1

2

3}, Claudia Martins^{1

2

3}, Layla Shbat^{1

2}, Marwa Abo Alsoud^{1

2}, Manuel Borod^{3

5}, Michael Wolfson⁶, Ioanna Papaioannou⁷, Olga Basso^{4

8}, John Sampalis^{7

9}

Affiliations

¹ McGill University Health Center, Gynecologic Cancer Services, Cancer Care Mission, 1001 Decarie Boulevard, Montreal, QC, H4A 3J1, Canada.
² McGill University, Department of Obstetrics & Gynecology, 1001 Decarie Boulevard, Montreal, QC, H4A 3 J1, Canada.
³ Department of Oncology, McGill University, 5100 de Maisonneuve Boulevard West, Montreal, QC, H4A 3T2, Canada.
⁴ Research Institute of The McGill University Health Center, 1001 Decarie Boulevard, Montreal, QC, H4A 3J1, Canada.
⁵ McGill University Health Center, Supportive & Palliative Care Services, Cancer Care Mission, 1001 Decarie Boulevard, Montreal, QC, H4A 3 J1, Canada.
⁶ University of Ottawa, Department of Epidemiology & Community Medicine, 600 Peter Morand Crescent, Ottawa, Canada, K1G 5Z3, Canada.
⁷ JSS Medical Research, 9400 Henri-Bourassa West, Montreal, QC, H4S 1N8, Canada.
⁸ Department of Epidemiology, Biostatistics, & Occupational Health, McGill University, 1020 Pine Avenue West, Montreal, QC, H3A 1A2, Canada.
⁹ McGill University, Faculty of Medicine, Department of Surgery, Division of Surgical Research, 1650 Cedar Avenue, Montreal, QC, H3G 1A4, Canada.

PMID: 32223298
DOI: 10.2217/cer-2020-0032

Abstract

Aim: To describe the direct healthcare costs associated with repeated cytotoxic chemotherapy treatments for recurrent high-grade serous cancer (HGSC) of the ovaries. Patients & methods: Retrospective review of 66 women with recurrent stage III/IV HGSC ovarian cancer treated with repeated lines of cytotoxic chemotherapy in a Canadian University Tertiary Center. Results: Mean cost of treatment of first relapse was CAD$52,227 increasing by 38% for two, and 86% for three or more relapses with median overall survival of 36.0, 50.7 and 42.8 months, respectively. In-hospital care accounted for 71% and chemotherapy drugs accounted for 17% of the total costs. Conclusion: After the third relapse of HGSC, cytotoxic chemotherapy did not prolong survival but was associated with substantially increased healthcare costs.

Keywords: cytotoxic chemotherapy; healthcare costs; recurrent high-grade serous ovarian cancer.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Aged
Canada
Cystadenocarcinoma, Serous / drug therapy*
Cystadenocarcinoma, Serous / economics*
Cytotoxins / therapeutic use
Female
Health Care Costs / statistics & numerical data*
Humans
Middle Aged
Neoplasm Recurrence, Local / drug therapy*
Neoplasm Recurrence, Local / economics*
Ovarian Neoplasms / drug therapy*
Ovarian Neoplasms / economics*
Retrospective Studies
Tertiary Care Centers

Substances

Cytotoxins